Northland Securities Lifts Earnings Estimates for Nephros

Nephros Inc. (NASDAQ:NEPH) – Research analysts at Northland Securities boosted their Q3 2026 earnings per share (EPS) estimates for Nephros in a research report issued to clients and investors on Thursday, August 13th. Northland Securities analyst B. Brooks now anticipates that the company will earn $0.02 per share for the quarter, up from their prior forecast of $0.01. Northland Securities currently has a “Market Perform” rating and a $4.00 price objective on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.15 per share. Northland Securities also issued estimates for Nephros’ FY2026 earnings at $0.15 EPS, Q2 2027 earnings at $0.17 EPS and FY2027 earnings at $0.31 EPS.

NEPH has been the topic of a number of other reports. Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. Zacks Research upgraded shares of Nephros to a “hold” rating in a report on Monday, July 20th. Three analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nephros Stock Down 6.7%

Shares of NEPH opened at $4.32 on Monday. The firm’s fifty day moving average is $3.59 and its two-hundred day moving average is $3.51. The stock has a market cap of $46.92 million, a PE ratio of 27.00 and a beta of 1.51. Nephros has a 52-week low of $2.66 and a 52-week high of $6.42.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter. Nephros had a return on equity of 10.60% and a net margin of 8.38%.The firm had revenue of $6.02 million for the quarter, compared to analyst estimates of $4.99 million.

Institutional Investors Weigh In On Nephros

Several hedge funds and other institutional investors have recently bought and sold shares of NEPH. De Lisle Partners LLP acquired a new stake in shares of Nephros during the 2nd quarter worth about $62,000. Bard Associates Inc. purchased a new position in Nephros during the second quarter worth about $421,000. BlackRock Inc. acquired a new stake in shares of Nephros during the second quarter valued at about $67,000. Cornerstone Capital Inc. acquired a new stake in shares of Nephros during the second quarter valued at about $459,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Nephros by 52.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after acquiring an additional 7,144 shares during the period. 41.10% of the stock is currently owned by institutional investors and hedge funds.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.